Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy

References

• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• D’AddarioGFrühMReckMBaumannPKlepetkoWFelipEfor ESMO Guidelines Working GroupMetastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5116119
   PubMed Web of Science ®Google Scholar
• BlanchonFGrivauxMCollonTEpidémiologie du cancer bronchique primitif pris en charge dans les centres hospitaliers généraux françaisRev Mal Respir200219672773412524492
   PubMed Web of Science ®Google Scholar
• YangPAllenMSAubryMCClinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003Chest2005128145246216002972
   PubMed Web of Science ®Google Scholar
• HowlanderNNooneAKrapchoM SEER Cancer Statistics Review, 1975–2008 [updated 2011]. Available from: http://seer.cancer.gov/csr/1975_2008/. Accessed September 15, 2011.
   Google Scholar
• GoldstrawPCrowleyJChanskyKThe IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumoursJ Thorac Oncol20072870671417762336
   PubMed Web of Science ®Google Scholar
• AzzoliCGBakerSJrTeminSAmerican Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancerJ Clin Oncol200927366251626619917871
   PubMed Web of Science ®Google Scholar
• NCCN Practice Guidelines in Oncology – Non-Small Cell Lung Cancer [updated 2011]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed September 15, 2011.
   Google Scholar
• MaionePRossiABareschinoMAFactors driving the choice of the best second-line treatment of advanced NSCLCRev Recent Clin Trials201161445120868346
   PubMedGoogle Scholar
• Erlotinib – Summary of Product Characteristics [updated June 7, 2011]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000618/WC500033994.pdf. Accessed September 15, 2011.
   Google Scholar
• Docetaxel – Summary of Product Characteristics [updated February 3, 2011]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002032/WC500101758.pdf. Accessed September 15, 2011.
   Google Scholar
• Pemetrexed – Summary of Product Characteristics [updated February 23, 2011]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000564/WC500025611.pdf. Accessed September 15, 2011.
   Google Scholar
• ScagliottiGVBeyond first-line treatment: expanding the optionsProceedings of the 2nd International Thoracic Oncology Congress Dresden (ITOCD), published in Session: Treatment strategies to extend survival in advanced NSCLC2010 Sep 16–18Dresden, Germany ITOCD 2010. http://www.itocd.com/.
   Google Scholar
• HawkinsNScottDAWoodsBSThatcherNNo study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant dataValue Health2009126996100319402854
   PubMed Web of Science ®Google Scholar
• ShepherdFARodriguesPJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• ShepherdFADanceyJRamlauRProspective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyJ Clin Oncol200018102095210310811675
   PubMed Web of Science ®Google Scholar
• FossellaFVDeVoreRKerrRNRandomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study GroupJ Clin Oncol200018122354236210856094
   PubMed Web of Science ®Google Scholar
• HannaNShepherdFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
   PubMed Web of Science ®Google Scholar
• VamvakasLAgelakiSKentepozidisNKPemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small-cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trialProceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting2010 June 4–8Chicago, IL, USA American Society of Clinical Oncology; J Clin Oncol. 2010;28(15S):7519.
   Google Scholar
• CiuleanuTStelmakhLCicenasSEstebanEErlotinib versus docetaxel or pemetrexed as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) and poor prognosis: efficacy and safety results from the phase III TITAN studyProceedings of the Chicago Multidisciplinary Symposium in Thoracic Oncology2010 Dec 9–11Chicago, IL, USA American Society for Radiation Oncology; J Thorac Oncol. 2010;5(12):LBOA5.
   Google Scholar
• BezjakATuDSeymourLSymptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21J Clin Oncol200624243831383716921034
   PubMed Web of Science ®Google Scholar
• DanceyJShepherdFAGrallaRJKimYSQuality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trialLung Cancer200443218319414739039
   PubMed Web of Science ®Google Scholar
• MillerVFossellaFVDe VoreRDocetaxel Benefits Lung Cancer Symptoms and Quality of Life in a Randomized Phase III Study of Non-Small Cell Lung Cancer Patients Previously Treated with Platinum-Based TherapyProceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting1999 May 15–191999Atlanta, GA, USA American Society of Clinical Oncology, 1999
   Google Scholar
• NewbyDHillSUse of pharmacoeconomics in prescribing research. Part 2: cost-minimization analysis – when are two therapies equal?J Clin Pharm Ther200328214515012713612
   PubMed Web of Science ®Google Scholar
• BriggsAHO’BrienBJThe death of cost-minimization analysis?Health Econ200110217918411252048
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKAErlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancerPharmacoeconomics2010281759220014878
   PubMed Web of Science ®Google Scholar
• AraújoAParenteBSotto-MayorRAn economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancerRev Port Pneumol200814680382719023496
   PubMed Web of Science ®Google Scholar
• CapriSOrabitoARillioGEconomic evaluation of erlotinib, docetaxel and pemetrexed as second line therapy in non-small cell lung cancer [in Italian]Pharmacoeconomics Ital Res Articles201092113124
   Google Scholar
• CarlsonJJReyesCOestreicherNLubeckDRamseySDVeenstraDLComparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC)Lung Cancer200861340541518295368
   PubMed Web of Science ®Google Scholar
• Doral StefaniSGiorgio SaggiaMVicino dos SantosEACost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspectiveJ Med Econ200811338339619450094
   PubMedGoogle Scholar
• GatzemeierUPirkOGabrielAKotowaWSecond-Line-Therapy for Non-Small Cell Lung Cancer (NSCLC) – a Retrospective Cost AnalysisTumor Diagnostik und Therapie2008294211217
   Google Scholar
• KotowaWGatzemeierUPirkOGabrielAHeigenerDA comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German health care perspectiveJ Med Econ2007103255271
   Google Scholar
• Italian ex-factory costs of erlotinib and docetaxel [updated 2011]. Available from: http://www.informatorefarmaceutico.it/. Accessed August 6, 2011.
   Google Scholar
• Chemotherapy administration costs in Italy (Tariffa unica convenzionale per le prestazioni di assistenza ospedaliera regole e tarife valide per l’anno 2009; Inpatient DRG 17 M 410; Daycare DRG 17 M 410) [updated 2010]. Available from: http://www.regioni.it/mhonarc/details_confpres.aspx?id=172630. Accessed August 18, 2011.
   Google Scholar
• BanzKBischoffHBrunnerMComparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and SpainLung Cancer201174352953421592611
   PubMed Web of Science ®Google Scholar
• MickischGGoreMEscudierBProcopioGWalzerSNuijtenMCosts of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinibBr J Cancer20101021808619920817
   PubMed Web of Science ®Google Scholar
• BrownBDiamantopoulosABernierJAn economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United KingdomValue Health200811579179918194407
   PubMed Web of Science ®Google Scholar